Effect of Concomitant Hydroxyurea Therapy with Rutin and Gallic Acid: Integration of Pharmacokinetic and Pharmacodynamic Approaches

[Image: see text] Hydroxyurea (HU) is the first-ever approved drug by USFDA for sickle cell anemia (SCA). However, its treatment is associated with severe side effects like myelosuppression. Current studies are focused on the supplementation therapy for symptomatic management of SCA. In the present...

Descripción completa

Detalles Bibliográficos
Autores principales: Gour, Abhishek, Dogra, Ashish, Kour, Dilpreet, Singh, Gurdarshan, Kumar, Ajay, Nandi, Utpal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2021
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8190911/
https://www.ncbi.nlm.nih.gov/pubmed/34124477
http://dx.doi.org/10.1021/acsomega.1c01518

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8190911/
https://www.ncbi.nlm.nih.gov/pubmed/34124477
http://dx.doi.org/10.1021/acsomega.1c01518

Ejemplares similares